#	Pagina
attuale pagina	/open-h2020/projects/207831/index.html
-1	/open-h2020/projects/195336/index.html
-2	/open-h2020/projects/193757/index.html
-3	/open-h2020/projects/217933/index.html

Opendata, web and dolomites

MONONANOCHEM

In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MONONANOCHEM project word cloud

Explore the words cloud of the MONONANOCHEM project. It provides you a very rough idea of what is the project "MONONANOCHEM" about.

3d vivo blood explored bortezomib last signals tam nanostructures antitumoural molecular 2d efficacy depends tissue murine peripheral cytotoxic nano strategy heterogeneity possibility strategies penetration immunogenic mediated recruited acid therapies appropriate enormously loaded death circulating excellent therapy tumour mnctfs progress receptors loading broad host vitro hyaluronic drug cytokines monocyte tumoural cell macrophages hardly chemotherapeutic cancer live tested therapeutic infiltrate mass tissues macrophage tumours recruitment cellular time monocytes drugs treatment models largely inducing glucans 50 formulations microenvironment abnormal bulk decorated consisting advantage dectin beta infiltration cells

Project "MONONANOCHEM" data sheet

The following table provides information about the project.

Coordinator	HUMANITAS MIRASOLE SPA Organization address address: VIA MANZONI 56 city: ROZZANO (MI) postcode: 20100 website: www.humanitas.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	168˙277 €
EC max contribution	168˙277 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2015
Funding Scheme	MSCA-IF-EF-ST
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	HUMANITAS MIRASOLE SPA HUMANITAS MIRASOLE SPA Organization address address: VIA MANZONI 56 city: ROZZANO (MI) postcode: 20100 website: www.humanitas.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROZZANO (MI))	coordinator	168˙277.00

Map

Project objective

The success of current antitumoural therapies largely depends on the availability of appropriate drug delivery strategies, which have to allow the penetration of these drugs through the tumoural microenvironment. The knowledge related to the cellular heterogeneity of the tumours has advanced enormously in the last years. Tumour associated macrophages (TAM) can represent up to 50% of the tumour mass. TAM are derived from circulating monocytes, which are recruited from the peripheral blood towards the tumour in response to a broad range of molecular signals (i.e. cytokines). Recently several studies are focused on the development of therapeutic strategies targeting TAM, however, the possibility to use monocytes, with excellent ability to infiltrate the abnormal tumoural tissue, to deliver chemotherapeutic drugs into the tumour has been hardly explored.

Here, we aim to use the host monocyte/macrophage cells, with high ability to infiltrate the tumoural tissues, to deliver nano-chemotherapeutic formulations into the bulk of the tumour. We will develop Nano-Formulations consisting in Hyaluronic Acid (HA) nanostructures decorated with beta-glucans, allowing the targeting of specific receptors on the host circulating monocytes (Dectin-1), and at the same time, the loading of chemotherapeutic drugs into these cells. Cytotoxic drugs inducing immunogenic cell death (i.e. bortezomib), and thus the recruitment of new monocytes, will be used to enhance the efficacy of the therapy. Overall, we will use Monocytes loaded with Nano-ChemoTherapeutic Formulations (MNCTFs) as a new strategy to deliver cytotoxic drugs towards the tumoural cells, taking advantage of the infiltration ability of the monocytes/macrophages into tumour microenvironment. The MNCTFs will be tested using appropriate in vitro 2D and 3D tumour models and in vivo murine tumour models. We expect that this new live-cell mediated drug delivery system will provide greater progress in the treatment of cancer.

Publications

List of publications.
year	authors and title	journal	last update
2017	Fernando Torres AndÃ³n, Elisabeth Digifico, Akihiro Maeda, Marco Erreni, Alberto Mantovani, MarÃa JosÃ© Alonso, Paola Allavena Targeting tumor associated macrophages: The new challenge for nanomedicine published pages: 103-113, ISSN: 1044-5323, DOI: 10.1016/j.smim.2017.09.004	Seminars in Immunology 34	2019-05-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MONONANOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MONONANOCHEM" are provided by the European Opendata Portal: CORDIS opendata.